Neofluidics is innovative California-based start-up in the growing field of microfluidics hoping to reinvent the high throughput process with our NeoPlate™ system that drastically reduces the costs of primary drug screening. Using lab-on-a-chip technology integrated into a consumable well plate, the small nanoliter volumes used effect an almost 99% reduction in primary screening costs, while at the same time reducing filling errors and simplifying workflows by allowing single step dilution. The technology has been designed to work with most existing robotic liquid handling systems making its adoption by industry a seamless process. The company has adapted the technology for other applications such as single-cell analysis which features a microfluidic network of trapping chambers designed to capture single cells from a larger, initial cell population which is useful in cancer, immunologic, and genetic research. Another version of the technology uses microscopic volumes for tissue organ modeling to test drug toxicity. Neofluidics is headquartered in Carlsbad, California. Started in 2014, it holds two proprietary patents for lab-on-a-chip technology and has five product lines, including applications in the petroleum and military market segments. Since the launch of our NeoPlate™ well plate in September of 2015, the company has fulfilled orders for numerous clients throughout North America and abroad.